Policy

Lessons learned from implementation of a pharmacist-delivered medication therapy management intervention in primary care can inform future studies and be adopted into real-world clinical settings.

A framework for the role of pharmaceuticals in value-based healthcare, practical examples from organizations that have made the transition, and implementation considerations.

In-depth interviews were conducted with 15 health plans to explore why plans collect or forgo race, ethnicity, and language (REL) data collection efforts, and the challenges encountered with collecting and using data for quality improvement.

Panelists talk about payment reform models, such as accountable care organizations and bundled payments, as a response to new treatments in oncology.

Panel members are asked to discuss what drives the cost of drugs in cancer care. They also discuss the role companion diagnostics and personalized medicine play in oncology.

In this segment, panelists address coverage strategies health plans may utilize to finance patient access to the combination treatment.

AJMC's Co-Editor-in-Chief, Michael E. Chernew, PhD, Lee N. Newcomer, MD, MHA, UnitedHealthcare, and Sandra M. Swain, MD, Washington Cancer Institute, Medstar Washington Hospital Center.

Keith Dunleavy, MD, President and CEO, Inovalon, addresses the importance of healthcare data and the digitization of medicine. Dr. Dunleavy states that having quality data allows for more accurate care on an individual level, along with cost savings and a better risk score.

Sarah Thomas, Vice President, Public Policy and Communications, NCQA, says there are three options for states looking to initiate health insurance exchanges (HIX): federally facilitated, state sponsored, and partnership models.

Karen Ignagni, President and CEO, America's Health Insurance Plans (AHIP), states that higher costs and reductions in health plan options were consequences of states that did not link Affordable Care Act insurance market reforms and the individual mandate.